CA2132874C - Methode de detection des acides nucleiques isoles dans des prelevements de selles de mammiferes et reactifs correspondants - Google Patents

Methode de detection des acides nucleiques isoles dans des prelevements de selles de mammiferes et reactifs correspondants Download PDF

Info

Publication number: CA2132874C
Authority: CA; Canada
Prior art keywords: nucleic acid; stool; neoplasm; buffer; concentration
Prior art date: 1992-04-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002132874A

Other languages

English (en)

Other versions

CA2132874A1 (fr

Inventor

Bert Vogelstein

Kenneth W. Kinzler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johns Hopkins University

Original Assignee

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-01

Filing date

1993-03-31

Publication date

2003-08-19

1993-03-31 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

1993-10-14 Publication of CA2132874A1 publication Critical patent/CA2132874A1/fr

2003-08-19 Application granted granted Critical

2003-08-19 Publication of CA2132874C publication Critical patent/CA2132874C/fr

2013-03-31 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 118
238000000034 method Methods 0.000 title claims abstract description 91
108020004707 nucleic acids Proteins 0.000 title claims abstract description 91
102000039446 nucleic acids Human genes 0.000 title claims abstract description 91
239000003153 chemical reaction reagent Substances 0.000 title abstract description 9
230000035772 mutation Effects 0.000 claims abstract description 27
206010028980 Neoplasm Diseases 0.000 claims description 63
239000000523 sample Substances 0.000 claims description 41
239000002773 nucleotide Substances 0.000 claims description 40
125000003729 nucleotide group Chemical group 0.000 claims description 40
238000009396 hybridization Methods 0.000 claims description 35
108091034117 Oligonucleotide Proteins 0.000 claims description 24
230000000295 complement effect Effects 0.000 claims description 23
230000003321 amplification Effects 0.000 claims description 13
238000003199 nucleic acid amplification method Methods 0.000 claims description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
239000000872 buffer Substances 0.000 claims description 12
230000027455 binding Effects 0.000 claims description 11
101710113436 GTPase KRas Proteins 0.000 claims description 10
238000001514 detection method Methods 0.000 claims description 10
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
108700020796 Oncogene Proteins 0.000 claims description 9
239000012139 lysis buffer Substances 0.000 claims description 9
230000003211 malignant effect Effects 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
239000002738 chelating agent Substances 0.000 claims description 7
108010014186 ras Proteins Proteins 0.000 claims description 7
206010009944 Colon cancer Diseases 0.000 claims description 6
239000011780 sodium chloride Substances 0.000 claims description 6
108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 5
102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 5
239000011521 glass Substances 0.000 claims description 5
208000003200 Adenoma Diseases 0.000 claims description 4
101710163270 Nuclease Proteins 0.000 claims description 4
239000007983 Tris buffer Substances 0.000 claims description 4
230000001580 bacterial effect Effects 0.000 claims description 4
210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
210000002429 large intestine Anatomy 0.000 claims description 4
210000000813 small intestine Anatomy 0.000 claims description 4
238000006467 substitution reaction Methods 0.000 claims description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
201000010989 colorectal carcinoma Diseases 0.000 claims description 3
238000012217 deletion Methods 0.000 claims description 3
230000037430 deletion Effects 0.000 claims description 3
238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 3
208000004804 Adenomatous Polyps Diseases 0.000 claims description 2
208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
206010024612 Lipoma Diseases 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
208000009956 adenocarcinoma Diseases 0.000 claims description 2
208000002458 carcinoid tumor Diseases 0.000 claims description 2
238000005119 centrifugation Methods 0.000 claims description 2
230000003196 chaotropic effect Effects 0.000 claims description 2
201000010260 leiomyoma Diseases 0.000 claims description 2
208000035269 cancer or benign tumor Diseases 0.000 claims 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
239000013618 particulate matter Substances 0.000 claims 2
108010067770 Endopeptidase K Proteins 0.000 claims 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 claims 1
239000012141 concentrate Substances 0.000 claims 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
208000010749 gastric carcinoma Diseases 0.000 claims 1
238000005342 ion exchange Methods 0.000 claims 1
239000011159 matrix material Substances 0.000 claims 1
230000002496 gastric effect Effects 0.000 abstract description 5
238000002955 isolation Methods 0.000 abstract 1
239000013615 primer Substances 0.000 description 51
108091028043 Nucleic acid sequence Proteins 0.000 description 35
108020004414 DNA Proteins 0.000 description 32
230000015572 biosynthetic process Effects 0.000 description 17
230000009826 neoplastic cell growth Effects 0.000 description 16
239000000243 solution Substances 0.000 description 16
238000003786 synthesis reaction Methods 0.000 description 16
241000282414 Homo sapiens Species 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 12
230000002285 radioactive effect Effects 0.000 description 12
108700042226 ras Genes Proteins 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
239000002253 acid Substances 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
238000006116 polymerization reaction Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
230000008569 process Effects 0.000 description 8
238000002105 Southern blotting Methods 0.000 description 7
238000003556 assay Methods 0.000 description 7
210000003050 axon Anatomy 0.000 description 7
101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 6
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
239000000203 mixture Substances 0.000 description 6
-1 nucleoside triphosphates Chemical class 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
102000043276 Oncogene Human genes 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000002934 lysing effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000000926 separation method Methods 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
108700020978 Proto-Oncogene Proteins 0.000 description 3
102000052575 Proto-Oncogene Human genes 0.000 description 3
101150040459 RAS gene Proteins 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000605 extraction Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
206010069754 Acquired gene mutation Diseases 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
206010064571 Gene mutation Diseases 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
102000001218 Rec A Recombinases Human genes 0.000 description 2
108010055016 Rec A Recombinases Proteins 0.000 description 2
238000007792 addition Methods 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
238000000137 annealing Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000037439 somatic mutation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical class C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
ISWSIDIOOBJBQZ-QYKNYGDISA-N 2-deuteriophenol Chemical compound [2H]C1=CC=CC=C1O ISWSIDIOOBJBQZ-QYKNYGDISA-N 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
235000016795 Cola Nutrition 0.000 description 1
241001634499 Cola Species 0.000 description 1
235000011824 Cola pachycarpa Nutrition 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
241000975394 Evechinus chloroticus Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
101150096040 GNAO1 gene Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
206010069755 K-ras gene mutation Diseases 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
102000043871 biotin binding protein Human genes 0.000 description 1
108700021042 biotin binding protein Proteins 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
235000021170 buffet Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
VUSHQLWDOJFSGF-UHFFFAOYSA-L disodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate chloride Chemical compound [Na+].[Na+].Cl.[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O VUSHQLWDOJFSGF-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000010437 gem Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
239000002987 primer (paints) Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000000376 reactant Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
229910001488 sodium perchlorate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Saccharide Compounds (AREA)

CA002132874A 1992-04-01 1993-03-31 Methode de detection des acides nucleiques isoles dans des prelevements de selles de mammiferes et reactifs correspondants Expired - Lifetime CA2132874C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86191092A	1992-04-01	1992-04-01
US861,910		1992-04-01
PCT/US1993/002960 WO1993020235A1 (fr)	1992-04-01	1993-03-31	Procedes de detection d'acides nucleiques de mammifere isoles a partir d'un echantillon de selles, et reactifs utilises a cet effet

Publications (2)

Publication Number	Publication Date
CA2132874A1 CA2132874A1 (fr)	1993-10-14
CA2132874C true CA2132874C (fr)	2003-08-19

Family

ID=25337083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002132874A Expired - Lifetime CA2132874C (fr)	1992-04-01	1993-03-31	Methode de detection des acides nucleiques isoles dans des prelevements de selles de mammiferes et reactifs correspondants

Country Status (8)

Country	Link
US (2)	US5910407A (fr)
EP (1)	EP0672181B1 (fr)
JP (1)	JP3633932B2 (fr)
AT (1)	ATE253645T1 (fr)
CA (1)	CA2132874C (fr)
DE (1)	DE69333289T2 (fr)
ES (1)	ES2210239T3 (fr)
WO (1)	WO1993020235A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5561041A (en) *	1993-11-12	1996-10-01	The Johns Hopkins University School Of Medicine	Nucleic acid mutation detection by analysis of sputum
US6235470B1 (en)	1993-11-12	2001-05-22	The Johns Hopkins University School Of Medicine	Detection of neoplasia by analysis of saliva
US5922544A (en) *	1994-12-29	1999-07-13	Eiken Kagaku Kabushiki Kaish	Method of cell detection
DE19530132C2 (de) *	1995-08-16	1998-07-16	Max Planck Gesellschaft	Verfahren zur Reinigung, Stabilisierung oder Isolierung von Nukleinsäuren aus biologischen Materialien
GB9518156D0 (en) *	1995-09-06	1995-11-08	Medical Res Council	Method of isolating cells
NO954667D0 (no)	1995-11-17	1995-11-17	Dagfinn Oegreid	Fremgangsmåte til deteksjon av Ki-ras mutasjoner
EP0920535B1 (fr) *	1996-08-26	2007-11-14	Invitek Gesellschaft für Biotechnik & Biodesign mbH.	Procede de detection de modifications cliniquement significatives de la sequence adn de l'oncogene ki-ras, son utilisation et kit d'essai pour le diagnostic precoce de tumeurs
US6406857B1 (en)	1997-06-16	2002-06-18	Exact Sciences Corporation	Methods for stool sample preparation
US6268136B1 (en)	1997-06-16	2001-07-31	Exact Science Corporation	Methods for stool sample preparation
EP0939118A1 (fr) *	1998-02-20	1999-09-01	Universiteit Maastricht	Procédé pour isoler de l'ADN et de l'ARN d'origine des fèces
US6280947B1 (en)	1999-08-11	2001-08-28	Exact Sciences Corporation	Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en)	1999-01-10	2003-01-07	Exact Sciences Corporation	Methods for detecting mutations using primer extension for detecting disease
AU752817B2 (en) *	1999-02-25	2002-10-03	Exact Sciences Corporation	Methods for preserving DNA integrity
EP1169479B1 (fr) *	1999-04-09	2006-06-28	EXACT Sciences Corporation	Procedes de detection d'acides nucleiques revelateurs de cancer
JP2003530817A (ja)	1999-06-01	2003-10-21	ベイラーカレッジオブメディスン	聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
US6586177B1 (en)	1999-09-08	2003-07-01	Exact Sciences Corporation	Methods for disease detection
US6849403B1 (en)	1999-09-08	2005-02-01	Exact Sciences Corporation	Apparatus and method for drug screening
PT1955700E (pt)	1999-09-30	2011-05-04	Harbor Biosciences Inc	Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
US6919174B1 (en)	1999-12-07	2005-07-19	Exact Sciences Corporation	Methods for disease detection
CA2394921A1 (fr) *	1999-12-07	2001-06-14	Anthony P. Shuber	Detection de neoplasmes aerodigestifs supracoliques
US7005266B2 (en)	2000-02-04	2006-02-28	Qiagen Gmbh	Nucleic acid isolation from stool samples and other inhibitor-rich biological materials
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
AU758744B2 (en) *	2000-10-31	2003-03-27	F. Hoffmann-La Roche Ag	Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain
US20060073530A1 (en) *	2001-08-15	2006-04-06	Olaf Schneewind	Methods and compositions involving sortase B
US20030165940A1 (en)	2001-12-06	2003-09-04	The Johns Hopkins University	Disease detection by digital protein truncation assays
EP1572902B1 (fr)	2002-02-01	2014-06-11	Life Technologies Corporation	Courts fragments d'arn interferant haute activite visant a reduire l'expression de genes cibles
US20060009409A1 (en)	2002-02-01	2006-01-12	Woolf Tod M	Double-stranded oligonucleotides
ATE556714T1 (de)	2002-02-01	2012-05-15	Life Technologies Corp	Doppelsträngige oligonukleotide
AU2003245465A1 (en) *	2002-02-13	2003-09-04	Medimolecular Pty. Ltd.	Method of isolating nucleic acids from stool samples
US7776524B2 (en) *	2002-02-15	2010-08-17	Genzyme Corporation	Methods for analysis of molecular events
US7482116B2 (en)	2002-06-07	2009-01-27	Dna Genotek Inc.	Compositions and methods for obtaining nucleic acids from sputum
KR20120002613A (ko)	2002-08-12	2012-01-06	제네렉스, 인코포레이티드	폭스바이러스 및 암과 관련된 방법 및 조성물
US20090305294A1 (en) *	2003-02-13	2009-12-10	Medimolecular Pty Ltd	Method of isolating nucleic acids from stool samples
US20040259101A1 (en) *	2003-06-20	2004-12-23	Shuber Anthony P.	Methods for disease screening
US7189068B2 (en) *	2003-09-19	2007-03-13	Gast Manufacturing, Inc.	Sound reduced rotary vane compressor
WO2005111244A2 (fr) *	2004-05-10	2005-11-24	Exact Sciences Corporation	Methodes de detection d'un acide nucleique mutant
WO2005113769A1 (fr) *	2004-05-14	2005-12-01	Exact Sciences Corporation	Procédé servant à stabiliser des échantillons biologiques pour une analyse d'acides nucléiques
WO2006026654A2 (fr)	2004-08-27	2006-03-09	Exact Sciences Corporation	Procede pour detecter une recombinaison
CA2581086C (fr)	2004-09-14	2023-11-07	The Regents Of The University Of Colorado, A Body Corporate	Procede de traitement faisant intervenir du bucindolol fonde sur le ciblage genetique
US9109256B2 (en)	2004-10-27	2015-08-18	Esoterix Genetic Laboratories, Llc	Method for monitoring disease progression or recurrence
US20090197249A1 (en)	2004-11-01	2009-08-06	George Mason University	Compositions and methods for diagnosing colon disorders
JP2006166711A (ja) *	2004-12-13	2006-06-29	Okayama Univ	糞便由来遺伝子の簡便増幅方法
US9777314B2 (en)	2005-04-21	2017-10-03	Esoterix Genetic Laboratories, Llc	Analysis of heterogeneous nucleic acid samples
US20070031867A1 (en) *	2005-06-27	2007-02-08	John Wayne Cancer Institute	Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
KR101772375B1 (ko) *	2005-09-07	2017-08-29	신라젠(주)	Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en)	2005-09-07	2015-03-17	Sillajen Biotherapeutics, Inc.	Oncolytic vaccinia virus cancer therapy
WO2009016433A2 (fr)	2006-09-15	2009-02-05	Ottawa Health Research Institute	Rhabdovirus oncolytique
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100310661A1 (en) *	2007-07-16	2010-12-09	Poniard Pharmaceuticals, Inc.	Oral formulations for picoplatin
CA2715348A1 (fr) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Utilisation de picoplatine et de bevacizumab pour traiter un cancer colorectal
CN102105583A (zh) *	2008-07-23	2011-06-22	奥林巴斯株式会社	从粪便试样中回收核酸的方法、核酸分析方法以及粪便试样处理装置
US9587270B2 (en)	2009-06-29	2017-03-07	Luminex Corporation	Chimeric primers with hairpin conformations and methods of using same
US9409983B2 (en)	2009-07-23	2016-08-09	The Board Of Trustess Of The University Of Illinois	Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9512481B2 (en)	2009-09-11	2016-12-06	The Regents Of The University Of Colorado, A Body Corporate	Polymorphisms in the PDE3A gene
ES2848650T3 (es)	2009-09-14	2021-08-11	Sillajen Biotherapeutics Inc	Terapia combinada contra el cáncer con virus vaccinia oncolítico
WO2011070440A2 (fr)	2009-12-10	2011-06-16	Ottawa Hospital Research Institute	Rhabdovirus oncolitique
ES2587191T3 (es)	2009-12-23	2016-10-21	Arca Biopharma, Inc.	Métodos y composiciones para enfermedades y afecciones cardiovasculares
AU2012204467B2 (en)	2011-01-04	2016-08-18	Sillajen, Inc.	Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2681566A2 (fr)	2011-02-28	2014-01-08	University of Iowa Research Foundation	Changements d'hormone antimullérienne dans la grossesse et prédiction d'évolution indésirable de grossesse et du sexe
AU2012226530B2 (en)	2011-03-08	2016-12-01	King Abdullah University Of Science And Technology	Molecular biomarker set for early detection of ovarian cancer
GB201107466D0 (en)	2011-05-05	2011-06-15	Loktionov Alexandre	Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
EP2718427B1 (fr)	2011-06-08	2017-01-11	Children's Hospital of Eastern Ontario Research Institute Inc.	Compositions pour le traitement du glioblastome
WO2012177656A2 (fr)	2011-06-19	2012-12-27	Abogen, Inc.	Dispositifs, solutions et procédés de recueillement d'échantillons
WO2013036799A2 (fr)	2011-09-09	2013-03-14	Fred Hutchinson Cancer Research Center	Procédés et compositions impliquant des inhibiteurs du nkg2d et le cancer
US10125373B2 (en)	2013-01-22	2018-11-13	Arizona Board Of Regents On Behalf Of Arizona State University	Geminiviral vector for expression of rituximab
JP2016513115A (ja)	2013-02-21	2016-05-12	チルドレンズホスピタルオブイースタンオンタリオリサーチインスティチュートインコーポレイテッド	ワクチン組成物
MX2016004283A (es)	2013-10-03	2016-10-12	Oklahoma Med Res Found	Biomarcadores para la actividad, e intesidad y arrebato de la enfermedad lupus eritematoso sistemico.
KR102392407B1 (ko)	2014-03-07	2022-04-29	디엔에이 제노텍 인코퍼레이티드	생물학적 샘플에서 핵산을 안정화하기 위한 조성물 및 방법
CA2969145A1 (fr)	2014-11-26	2016-06-02	The Regents Of The University Of California	Compositions therapeutiques comprenant des facteurs de transcription et leurs procedes de preparation et d'utilisation
AU2018213315A1 (en)	2017-01-26	2019-07-25	Oklahoma Medical Research Foundation	Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US12140592B2 (en)	2017-06-16	2024-11-12	Oklahoma Medical Research Foundation	Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
MX2020014243A (es)	2018-06-19	2021-05-12	Biontech Us Inc	Neoantigenos y usos de los mismos.
US20210349088A1 (en)	2018-10-18	2021-11-11	Oklahoma Medical Research Foundation	Biomarkers For A Systemic Lupus Erythematosus (SLE) Disease Activity Immune Index That Characterizes Disease Activity
US12510539B2 (en)	2018-10-18	2025-12-30	Progentec Diagnostics, Inc.	Biomarkers for a systemic lupus erythematosus (SLE) disease activity immune index that characterizes disease activity
CN113614535B (zh)	2018-10-31	2024-08-16	亚利桑那大学评议会	用于辐射诱导的肺损伤的生物标志物和使用方法
US20220296622A1 (en)	2019-09-16	2022-09-22	The Children's Hospital Of Philadelphia	Compositions and methods for the treatment of swi-snf mutant tumors
CN113186185B (zh) *	2020-01-14	2023-05-26	东北林业大学	一种从哺乳动物粪便中高效富集宿主dna的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4358535A (en)	1980-12-08	1982-11-09	Board Of Regents Of The University Of Washington	Specific DNA probes in diagnostic microbiology
US5482834A (en) *	1982-05-17	1996-01-09	Hahnemann University	Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells
US5037959A (en) *	1984-05-29	1991-08-06	Lubrizol Genetics, Inc.	Self incompatibility protein
FR2567541B1 (fr)	1984-07-13	1987-02-06	Pasteur Institut	Sonde d'adn et procede pour la detection de " shigelles " et des souches entero-invasives de escherichia coli
US4800159A (en) *	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5053331A (en) *	1986-04-21	1991-10-01	Lubrizol Genetics, Inc.	Self-incompatibility gene
US4935342A (en) *	1986-12-01	1990-06-19	Syngene, Inc.	Method of isolating and purifying nucleic acids from biological samples
US5024934A (en)	1988-03-14	1991-06-18	The Board Of Regents, The University Of Texas System	Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification
US5362623A (en) *	1991-06-14	1994-11-08	The John Hopkins University	Sequence specific DNA binding by p53
AU7224591A (en)	1990-01-24	1991-08-21	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	A rapid and sensitive test for detecting hepatitis a virus
US5352775A (en) *	1991-01-16	1994-10-04	The Johns Hopkins Univ.	APC gene and nucleic acid probes derived therefrom
US5330892A (en) *	1991-03-13	1994-07-19	The Johns Hopkins University	MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
US5670325A (en) *	1996-08-14	1997-09-23	Exact Laboratories, Inc.	Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5612473A (en) *	1996-01-16	1997-03-18	Gull Laboratories	Methods, kits and solutions for preparing sample material for nucleic acid amplification

1993
- 1993-03-31 JP JP51762893A patent/JP3633932B2/ja not_active Expired - Fee Related
- 1993-03-31 DE DE69333289T patent/DE69333289T2/de not_active Expired - Lifetime
- 1993-03-31 AT AT93909210T patent/ATE253645T1/de not_active IP Right Cessation
- 1993-03-31 EP EP93909210A patent/EP0672181B1/fr not_active Expired - Lifetime
- 1993-03-31 WO PCT/US1993/002960 patent/WO1993020235A1/fr not_active Ceased
- 1993-03-31 CA CA002132874A patent/CA2132874C/fr not_active Expired - Lifetime
- 1993-03-31 ES ES93909210T patent/ES2210239T3/es not_active Expired - Lifetime
1994
- 1994-08-26 US US08/297,265 patent/US5910407A/en not_active Expired - Lifetime
1999
- 1999-06-08 US US09/328,114 patent/US6177251B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2132874A1 (fr)	1993-10-14
JPH08504081A (ja)	1996-05-07
DE69333289T2 (de)	2004-08-26
JP3633932B2 (ja)	2005-03-30
EP0672181A4 (fr)	1997-03-26
ES2210239T3 (es)	2004-07-01
US5910407A (en)	1999-06-08
WO1993020235A1 (fr)	1993-10-14
EP0672181B1 (fr)	2003-11-05
EP0672181A1 (fr)	1995-09-20
ATE253645T1 (de)	2003-11-15
US6177251B1 (en)	2001-01-23
DE69333289D1 (de)	2003-12-11

Legal Events

Date	Code	Title	Description
1998-05-22	EEER	Examination request

Publication	Publication Date	Title
CA2132874C (fr)	2003-08-19	Methode de detection des acides nucleiques isoles dans des prelevements de selles de mammiferes et reactifs correspondants
US7601521B2 (en)	2009-10-13	Detection of nucleic acid mutation associated with cancer by analysis of saliva
EP0728217B1 (fr)	2004-05-26	Methode de detection d'acides nucleiques contenant des mutations par analyse des crachats
EP0868529B1 (fr)	2003-10-01	Procede de detection des mutations ki-ras et son necessaire de mie en oeuvre
EP1690948A2 (fr)	2006-08-16	Detection spécifique de la méthylation
WO2003000112A2 (fr)	2003-01-03	Utilisation de la rnase l dependant de 2',5'-oligoadenylate inductible par l'interferon dans le diagnostic, le pronostic et le traitement du cancer
CA2612690C (fr)	2012-04-24	Detection specifique de la methylation
Rapakko	2007	Hereditary predisposition to breast cancer—evaluation of candidate genes
Dong	2003	Molecular genetic studies of oligodendroglial tumors
HK1033765B (en)	2009-11-13	Detection of neoplasia by analysis of saliva